The US Food and Drug Administration has approved AbbVie's (ABBV) treatment for Parkinson's disease in adults, according to the regulator's website.

BridgeBio Pharma (BBIO) expects 2027 to mark its transformation from a one-product company into a group with four globally launched therapies, according to Thomas Trimarchi, its president and chief financial officer, speaking at a Bernstein conference.

Florida's attorney-general is suing three drugmakers and three pharmacy benefit managers, alleging they worked together to inflate insulin prices and profit from the increases.

Shares in Nanexa (NANEXA) more than doubled in early trading last month after the Swedish drug-delivery company signed a global licensing agreement with Novo Nordisk (NVO) worth up to about €1.17bn ($1.33bn).

Shares in Ascendis Pharma (ASND) fell 6.1 per cent after the company said it would take back full rights to its metabolic and cardiovascular programs following the end of its collaboration with Novo Nordisk (NVO).

Shares in ADARx Pharmaceuticals (ADRX) rose 30 per cent above their offer price in Nasdaq debut trading after the late-stage gene therapy developer raised $446.3mn in an upsized US initial public offering.

Dr Reddy's Laboratories (RDY) announced it had signed an agreement with Japanese drugmaker Takeda Pharmaceutical (TAK) to promote and distribute the Qdenga dengue vaccine in India.

AstraZeneca (AZN) and Daiichi Sankyo (4568) said that their breast cancer treatment Enhertu has been approved for use in England's state-run healthcare system, widening access to a drug that has been available in Scotland since 2023.

BridgeBio Pharma (BBIO) said its heart drug acoramidis outperformed tafamidis in a new peer-reviewed, real-world study of patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive disease of the heart muscle.

Anthropic has quietly set up a laboratory for physical biology work, extending its artificial intelligence ambitions into drug science, according to two people familiar with the matter.

The US Food and Drug Administration has approved a combination of two Eli Lilly (LLY) pills for adults with a form of advanced breast cancer that has spread to other parts of the body, the drugmaker announced.

Roche (RHHBY) has scored another win for its T-cell engager portfolio, after a phase 3 trial showed its drug Lunsumio improved outcomes for patients with follicular lymphoma who have received earlier treatment.

Telix Pharmaceuticals (TLX) has agreed to acquire Germany's ITM Isotope Technologies Munich for about $1.65bn on a cash- and debt-free basis, in a deal that deepens the Australian company's push into radiopharmaceuticals.

President Donald Trump announced that all 50 states, the District of Columbia and Puerto Rico will take part in his most-favored-nation drug pricing scheme for Medicaid, the health program for low-income Americans.

The US is drafting rules on pharmaceutical investment in China that would probably preserve the ability of American drugmakers to strike most licensing deals for Chinese medicines, according to three people briefed on the process.

A group of independent pharmacies in Arkansas has sued Express Scripts, the Cigna (CI) unit that is among the largest pharmacy benefit managers in the US, alleging it underpaid for tens of thousands of prescriptions.

AbbVie (ABBV) announced that its migraine drug atogepant reduced the number of migraine days linked to menstruation in a late-stage study, potentially opening a new use for the treatment.

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) face a harder path to establishing their blockbuster antibody-drug conjugate Enhertu as a first-line treatment for HER2-mutant non-small cell lung cancer, after a late-stage trial showed an unfavorable trend in overall survival.

GE HealthCare (GEHC) is in talks over a possible deal worth about $1bn to acquire Sofie Biosciences, a developer of radioactive chemicals used in cancer imaging, according to people familiar with the matter.

Akeso (9926.HK) and Summit Therapeutics (SMMT) have reported that their experimental drug ivonescimab cut the risk of death by 27 percent compared with Merck & Co's (MRK) blockbuster Keytruda, strengthening the case for a class of cancer medicines that has drawn billions of dollars in industry investment.